- About WXPress
- WXPress is your window into the world of WuXi AppTec and our global partners.
- Sitemap
- Events
- Contact
- Please reach out with any business inquires.
- communications@wuxiapptec.com
© 2026 WuXi AppTec. All Rights Reserved.Privacy Policy
July 22, 2022 ~ July 22, 2022
8:00am - 10:am PDT | 11:00am - 1:00pm EDT
7:00pm - 9:00pm PDT | 10:00pm - 12:00am EDT
In commemorating Fragile X Syndrome Awareness Day on July 22nd, we are proud to have co-hosted the special virtual event, “Fragile X Syndrome: Innovative Approaches to Finding a Cure,” again alongside the FRAXA Research Foundation. Together we were able to enhance public awareness of Fragile X, and provide a global stage for key stakeholders to collaborate in order to overcome any barriers standing in the way of finding a cure for this devastating rare disease.
This is the 10th episode of our “Collaborations That Transform” series dedicated to rare disease patients. At WuXi AppTec, we are committed to providing a platform serving to catalyze transformational change for patients.
Special thanks to our 30+ distinguished speakers, and our supportive partners: Fragile X Association of Australia, Fragile X Association of China, Fragile X Society India, Fragile X Syndrome Parent’s Group Argentina, Fragile X South Africa, and Fragile X Center Georgia.
You are welcome to watch the on-demand video by clicking on the banner image above, or by visiting our WuXi AppTec YouTube Channel. Please follow us on Twitter and LinkedIn to stay up-to-date on upcoming WuXi AppTec news and events.
Below are our past events in the “Collaborations that Transform” series.
2022:
Moving the Needle on ALS & Neuromuscular Disorders
2021:
DMD: Charting the Path for New Therapeutics and Better Care
Fragile X Syndrome: In Pursuit of a Cure
Winning the War on Huntington’s Disease
Progress in Halting Pompe Disease
WuXi Rare Disease Awareness Concert on International Rare Disease Day 2021
2020:
Emerging Opportunities in Multiple Sclerosis and Neuroscience
Spinal Muscular Atrophy (SMA)
Advances in Rare Diseases: Hemophilia
Neurofibromatosis
Hui Cai, Program Chair, VP and Head of Content, WuXi AppTec
Katie Clapp, President & Co-Founder, FRAXA Research Foundation
Elizabeth Berry-Kravis, Professor of Pediatrics, Neurological Sciences, Anatomy and Cell Biology, Rush University Medical Center
Peter Kind, Director, Simons Initiative for the Developing Brain, Patrick Wild Centre; Professor of Developmental Neuroscience, University of Edinburgh
Session Leader: Michael Tranfaglia, Medical Director & CSO, FRAXA Research Foundation
Hosts: Wendy Bruce, Executive Director, Fragile X Association of Australia, and Jeannie Lee, Vice Chair of Molecular Biology, MGH; Professor of Genetics, Harvard Medical School.
David Hampson, Professor, Department of Pharmaceutical Sciences, University of Toronto
Ralph Laufer, CSO, Lysogene
Ernest Pedapati, Associate Professor, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine
Kathryn Whitehead, Professor, Departments of Chemical Engineering and Biomedical Engineering, Carnegie Mellon University
Hosts: Mark Bear, Professor of Neuroscience, Picower Institute for Learning and Memory, MIT, and Craig Erickson, Professor of Clinical Psychiatry, Cincinnati Children's Hospital and the University of Cincinnati College of Medicine.
Daniel Alkon, President, CSO & Scientific Founder, Synaptogenix
John Atack, Director, Medicines Discovery Institute, Cardiff University
Mara Dierssen, Senior Scientist, Center for Genomic Regulation
Lynn Durham, Founder & CEO, STALICLA
Lili Mao, Head of Project Management Office and Director, Clinical Development Unit, GEXVal
Christopher Missling, President & CEO, Anavex Life Sciences
Adrian Newman-Tancredi, CEO, Neurolixis
Stephen O'Quinn, VP, Medical Affairs, Zynerba Pharmaceuticals
Robert Ring, CEO, Kaerus Bioscience
Fabio Tucci, COO & Co-Founder, Epigen Biosciences
David Walker, Director of Chemistry, Sentinel Oncology
Hosts: Bruce Bloom, Chief Collaboration Officer, Healx, and Andres Centellas, Board Member, FRAXA Research Foundation.
Isaac Bentwich, Founder & CEO, Quris
Randall Carpenter, Co-Founder, Allos Pharma
George Drakakis, CEO, Purposeful
Michael Hayden, Founder & CEO, Prilenia Therapeutics; Killam Professor, University of British Columbia
Mahmoud Pouladi, Associate Professor, Department of Medical Genetics, Faculty of Medicine, University of British Columbia
Nik Subramanian, CTO & Co-Founder, Kantify
Gordon Wang, Clinical Associate Professor, Department of Psychiatry & Behavioral Sciences; Director, Neuroscience Microscopy Service, Wu Tsai Neurosciences Institute, Stanford University
Xinyu Zhao, Jenni and Kyle Professor, Waisman Center and Department of Neuroscience, University of Wisconsin-Madison
Richard Soll, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec
